Clarivate™

Content highlights

Release date
December 2024

Geography
China

Primary research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 neurologists.

Epidemiology
Diagnosed prevalence of Alzheimer's disease in urban versus rural China; clinically relevant and commercially relevant drug-treated populations.

Forecast
10-year, annualized, drug-level sales and patient share of key Alzheimer's disease therapies through 2033, based on primary and secondary market research to formulate bottom-up assumptions.

Emerging therapies
Phase III/PR: 5+ drugs

Alzheimer's Disease
Spotlight on China In-Depth

Market outlook

Alzheimer's disease (AD) is a progressive and irreversible brain disorder that leads to a decline in cognitive abilities, affecting memory and causing patients' quality of life to deteriorate. AD patients are typically managed with symptomatic treatments that offer modest clinical benefit for a limited period, leaving substantial opportunity for therapies that can delay the disease's progression. Despite multiple late-phase failures, pharma companies continue to invest heavily in disease-modifying approaches to AD, owing to this market's tremendous clinical and commercial opportunity. With the recent approval of Eisai's Leqembi and the expected entry of multiple antiamyloid MAbs, this market is expected to expand significantly over the 2023-2033 forecast period. This report provides a comprehensive analysis of the AD therapy market in China, including current disease management, lingering unmet needs, and the clinical and commercial potential of current and emerging drugs.

Questions answered

- How large is China's drug-treatable AD population, and how will drug-treatment rates change during the forecast period?
- What are interviewed experts' insights into current treatment options?
- What are the key unmet needs in the management of AD in China?
- What are the key market access considerations for therapies in the AD pipeline in China? What sales/uptake could they secure in AD?
- What are the key drivers of and constraints in China's AD therapy market, and how will the market evolve over the forecast period?

Product description

China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.

NEW: China In-Depth reports include a **custom drug modeler**. This tool enables clients to input their own assumptions for a drug and forecast three scenarios that can be directly compared with Clarivate's projections for drugs included in the patient-based market forecast. To access the tool, download the Market Forecast Dashboard file on the Insights Platform.

Learn more about Clarivate's full suite of Alzheimer's disease solutions:

healthcare.support@clarivate.com   clarivate.com